Clin2
NCT07694336Possibly a fitRecruiting

Quinacrine for skin lupus

Cutaneous Lupus Erythematosus (CLE)

Part of Skin clinical trials.

This study tests if quinacrine, an oral drug, improves skin rashes caused by lupus. You may be eligible if you have a type of skin lupus called SCLE or DLE that hasn't improved with standard treatments like steroids or hydroxychloroquine.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
24 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have a confirmed diagnosis of SCLE or DLE (skin lupus) with active rash needing treatment.
  • Your rash severity score is at least 8 on a scale used by doctors.
  • You've tried standard treatments like topical steroids and hydroxychloroquine for at least 12 weeks without success or had side effects.
  • You are not taking certain medicines that can interfere with the study drug, and you don't have certain health conditions like liver problems or low kidney function.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT01510067Recruiting
Study of skin lupus types and how severe they are

This study looks at adults with cutaneous lupus (skin lupus) and/or systemic lupus (a whole-body autoimmune condition) to understand how common it is and how severe the skin symptoms become. It may help researchers better describe different skin lupus forms and their impact.

Philadelphia, Pennsylvania
NCT07440537Recruiting· Phase 2
Testing ICP-488 for active cutaneous lupus (skin lupus)

This trial tests an experimental drug called ICP-488 for people with active cutaneous lupus erythematosus (CLE), a type of lupus that affects the skin. It aims to see if the drug can reduce skin inflammation and improve symptoms.

Hefei, Anhui
NCT06965244Not yet recruiting· Phase 3
Lenalidomide vs methotrexate for hard-to-treat lupus skin disease

This trial compares two drugs, lenalidomide and methotrexate, to see which works better for people with active cutaneous lupus (skin lupus) that hasn't improved with standard treatments. You would be randomly assigned to one of the two drugs and followed for several months.

NCT07306585Not yet recruiting· Phase 1
Testing a new lupus drug for safety and early effects

This study tests a new injectable drug, HC022, for people with lupus or cutaneous lupus. It aims to see if the drug is safe, tolerable, and begins to work.

Beijing, Beijing Municipality
NCT07260877Recruiting· Phase 2
Testing VENT-03 for active skin lupus with or without systemic lupus

This study tests an experimental medicine called VENT-03 to see if it can improve skin lupus symptoms in adults. It compares VENT-03 against a placebo (a pill with no active drug) and includes a longer-term option where everyone can get the real drug. The goal is to find a new treatment for people whose lupus affects their skin.

Beverly Hills, California
NCT07332481Recruiting· Phase 3
Testing enpatoran for lupus affecting the skin

This trial tests if a drug called enpatoran can help people with lupus that causes skin rashes, like discoid lupus or subacute cutaneous lupus. It may be for those with or without systemic lupus.

Los Angeles, California

Hear when a new Cutaneous Lupus Erythematosus (CLE) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.